When something gets this much attention, we like to slow down and ask questions
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas
The group argued that where there is a legitimate patient need, allowing peptides to be compounded by state-licensed pharmacies would provide greater oversight through prescription requirements, quality standards, inspections and adverse-event reporting
Readers interested in how the same molecule is being examined from the appetite side can compare this analysis with the companion discussion of cagrilintides role in appetite regulation, which focuses on the central satiety arm rather than the gastrointestinal one
It's the unglamorous part that determines whether everything else matters
It should not be used by individuals with uncontrolled hypertension, a seizure disorder, or an eating disorder like anorexia or bulimia